神经内分泌肿瘤患者离开核医学科时1米处等效剂量率测量
该研究测量了93例神经内分泌肿瘤患者离开核医学科时胸骨和膀胱方向1米处等效剂量率(EDR-1m),共103对测量值。68Ga-DOTATOC或123I-MIBG注射患者的平均EDR-1m约为其他放射性药物注射患者的一半,所有患者EDR-1m均低于20 μSv/h。作者认为现行离院做法从辐射防护角度看似安全,限制性建议不必要。
要点
- 所有神经内分泌肿瘤患者离院时胸骨和膀胱方向1米处等效剂量率均低于20 μSv/h。
- 68Ga-DOTATOC或123I-MIBG注射患者的平均EDR-1m约为其他放射性药物注射患者的一半。
- 作者认为现行离院做法从辐射防护角度看似安全,限制性建议不必要。
核心结论
- 作者认为,现行允许患者在PET/CT显像后或SPECT放射性药物注射后离院的实践,从辐射防护角度看似乎安全。
- 作者认为,对离开核医学科的神经内分泌肿瘤患者,限制性建议是不必要的。
研究设计与样本
- 本研究在作者所在中心测量了93例神经内分泌肿瘤患者离开核医学科时的剂量率。
- 共获得103对胸骨和膀胱方向1米处等效剂量率(EDR-1m)配对测量值,探测器正对患者胸骨或膀胱、距离1米。
- 离院做法因转诊检查类型而异:PET/CT患者在显像后离院,SPECT/CT患者在放射性药物注射后即提前离院。
主要发现
- 53例68Ga-DOTATOC PET/CT检查的中位给药活度为122 MBq,胸骨方向中位EDR-1m为4.8 μSv/h,膀胱方向为5.1 μSv/h。
- 15例18F-FDOPA PET/CT检查的中位给药活度为198 MBq,胸骨方向中位EDR-1m为9.5 μSv/h,膀胱方向为10.1 μSv/h。
- 13例18F-FDG PET/CT检查的中位给药活度为176 MBq,胸骨方向中位EDR-1m为8.8 μSv/h,膀胱方向为9.5 μSv/h。
- 12例111In-pentetreotide SPECT/CT检查的中位给药活度为170 MBq,胸骨方向中位EDR-1m为9.4 μSv/h,膀胱方向为9.3 μSv/h。
- 10例123I-MIBG SPECT/CT检查的中位给药活度为186 MBq,胸骨方向中位EDR-1m为4.9 μSv/h,膀胱方向为4.7 μSv/h。
关键数值与推荐
- 所有神经内分泌肿瘤患者离院时胸骨和膀胱方向1米处等效剂量率均低于20 μSv/h。
- 68Ga-DOTATOC PET/CT中位给药活度122 MBq,胸骨方向中位EDR-1m 4.8 μSv/h、膀胱方向5.1 μSv/h。
- 18F-FDOPA PET/CT中位给药活度198 MBq,胸骨方向中位EDR-1m 9.5 μSv/h、膀胱方向10.1 μSv/h。
- 18F-FDG PET/CT中位给药活度176 MBq,胸骨方向中位EDR-1m 8.8 μSv/h、膀胱方向9.5 μSv/h。
- 111In-pentetreotide SPECT/CT中位给药活度170 MBq,胸骨方向中位EDR-1m 9.4 μSv/h、膀胱方向9.3 μSv/h;123I-MIBG SPECT/CT中位给药活度186 MBq,胸骨方向4.9 μSv/h、膀胱方向4.7 μSv/h。
临床怎么用
- 作者所在中心的现行做法是:PET/CT患者在显像后离院,SPECT/CT患者在放射性药物注射后即离院。
- 作者认为,该离院做法从辐射防护角度看似乎安全,对离院的神经内分泌肿瘤患者限制性建议不必要。
- 作者认为,68Ga-DOTATOC或123I-MIBG注射患者离院时EDR-1m约为其他放射性药物注射患者的一半,这为用PET生长抑素受体显像替代SPECT提供了补充论据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
123I-metaiodobenzylguanidine (MIBG) and 111In-pentetrotide SPECT have been used for functional imaging of neuroendocrine tumors (NETs) for the last 2 decades. More recently, PET/CT imaging with 18F-FDG, 18F-fluorodihydroxyphenylalanine (FDOPA), and 68Ga somatostatin-receptor ligands in NETs has been expanding. A literature search could find no direct measurements of the dose rate from NET patients exiting the nuclear medicine department after undergoing PET/CT with 18F-FDOPA or 68Ga-DOTATOC, a somatostatin analog. Methods: We measured the dose rates from 93 NET patients on leaving the department after undergoing PET/CT or SPECT/CT in our centers. In total, 103 paired measurements of equivalent dose rate at 1 m (EDR-1m) from the sternum and urinary bladder were obtained. The detector faced the sternum or bladder and was 1 m away from and directly in front of the patient. The practice for exiting the department differed according to whether the patient had been referred for PET/CT or for SPECT/CT. PET/CT patients were discharged after imaging, whereas SPECT/CT patients left the department earlier, just after radiopharmaceutical injection. Results: The median administered activity was 122 MBq in 53 68Ga-DOTATOC PET/CT studies, 198 MBq in 15 18F-FDOPA PET/CT studies, and 176 MBq in 13 18F-FDG PET/CT studies. The corresponding median EDR-1m was 4.8, 9.5, and 8.8 μSv/h, respectively, facing the sternum, and 5.1, 10.1, and 9.5 μSv/h, respectively, facing the bladder. The median administered activity was 170 MBq in 12 111In-pentetreotide SPECT/CT studies and 186 MBq in 10 123I-MIBG SPECT/CT studies. The corresponding median EDR-1m was 9.4, and 4.9 μSv/h, respectively, at the level of the sternum, and 9.3 and 4.7 μSv/h, respectively, at the level of the bladder. The EDR-1m was less than 20 μSv/h in all patients. Thus, when exiting the nuclear medicine department, the NET patients injected with 68Ga-DOTATOC or 123I MIBG emitted an average EDR-1m roughly half that of patients injected with other radiopharmaceuticals. This finding is a complementary argument for replacing SPECT by PET somatostatin-receptor imaging. Conclusion: Our current practice of allowing patients to exit after PET/CT imaging or just after SPECT radiopharmaceutical injection appears to be safe from a radiation protection point of view. Restrictive advice is unnecessary for NET patients being discharged from the department.
引用
- Zhang-Yin J, Dirand AS, Sasanelli M, et al. Equivalent Dose Rate 1 Meter from Neuroendocrine Tumor Patients Exiting the Nuclear Medicine Department After Undergoing Imaging. J Nucl Med. 2017. PMID: 28209907. doi:10.2967/jnumed.116.187138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。